CATEGORIES: CMT Update | Research

New Collaboration with the University of North Carolina at Chapel Hill and The Jackson Laboratory Addresses Charcot-MarieTooth/Inherited Neuropathy Mutations Using Gene Therapy

by | Apr 24, 2017 | 3 comments

Gene therapy represents an exciting new frontier being explored for treating a number of diseases. Currently, gene therapy is being used in a clinical trial to treat one of the rare forms of inherited neuropathy (IN), giant axonal neuropathy (GAN). Because of the potential gene therapy holds for treating a range of CMT/IN mutations-including the rarer ones—HNF is excited to announce a collaboration with the University of North Carolina at Chapel Hill and The Jackson Laboratory to begin the development of gene therapy approaches for Charcot-Marie-Tooth (CMT) and Inherited Neuropathies (IN). 

To start, our initial gene therapy work will focus on CMT type 6, which is caused by a recessive mutation in the C12orf65 gene and for which there is currently no treatment. CMT type 6 presents in patients with many of the typical symptoms associated with most types of CMT, but usually includes additional, significant impacts on vision and breathing that further challenge a patient’s quality of life.  And, unlike other forms of CMT, CMT type 6 is ultimately fatal. 

The CMT type 6 research that HNF is funding aims to replace the nonfunctional gene with a working copy.  Dr. Robert Burgess, lead co-investigator for this project, has developed a CMT type 6 mouse model to conduct a proof of concept study to determine the viability of using this approach to treat the disease. Dr. Steven Gray, assistant professor at the University of North Carolina, will be developing the gene therapy vector to be tested using this unique mouse model.  We are pleased to have Dr. Gray on this project’s team as his previous work was responsible for bringing the GAN gene therapy to a clinical trial.  Ensuring the success of this gene therapy approach will depend on getting everyone—health care providers and  CMT type 6 patients and their families— involved! Besides the work in the CMT type 6 mouse, patient specimens are extremely valuable for research. HNF will need to obtain skin fibroblasts from CMT type 6 patients that have a confirmed diagnosis. HNF will rely on its Centers of Excellence network and other medical institutions to obtain the skin fibroblasts needed to be sent to The Jackson Laboratory for further testing. 

Advancing a research project like this is a major undertaking requiring significant human, physical, and financial resources— however, the possibilities of achieving significant outcomes are unprecedented. To secure the ability of this project’s momentum, HNF has launched the Gene Therapy Fund to support this project’s efforts to tackle additional types of CMT/IN that warrant a gene therapy approach to treat CMT. The Gene Therapy Fund will be used and supported with the collaboration of Lori Sames (co-founder of Hannah’s Hope Fund and the tireless champion of the first gene therapy ever used for any  form of IN), UNC and The Jackson Laboratory.

We need your help! Here’s how to get involved: I support gene therapy research, and I want to enroll as a patient! If you are a patient with CMT and want to be part of this new initiative, please join the Global Registry for Inherited Neuropathies (GRIN). If you have any type of CMT/IN or do not know your type, join here: CLICK HERE

If you are interested in having your mutation added  to the list or in championing a gene therapy approach for  your type of CMT/IN, please contact Allison Moore at [email protected].

I support gene therapy research, and I want to make  a donation!

Your donations are crucial to making this research possible.

PLEASE DONATE TODAY

Learn more on this topic

Related Blog Posts

The Long Road to Diagnosis Renews Dedication to Advocacy

The Long Road to Diagnosis Renews Dedication to Advocacy

Growing up we called it “Steffi disorder.” My friends and family were as baffled as my expert neurologists. I had been diagnosed with typical Spiral Muscular Atrophy (SMA) as a toddler but never followed its progression; I never seemed to get weaker. My myriad of symptoms was distinctly different than anyone else’s I had ever met in a lifetime living in the neuromuscular community. I thought I might never find my true diagnosis, let alone others who share it with me.

A New Mouse Model for Charcot-Marie-Tooth (CMT2)

We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation.

Sixth Annual Card Party Brunch

On January 23, 2015 dedicated H.E.L.P. (Help Elliot Live Proud) Fund supporters participated in the 6th Annual Card Party Brunch and Boutique at Broken Sound County Club, Boca Raton, Florida. Record numbers flocked into the picturesque country club for a day filled with gourmet food, raffles, cards and a silent auction! HNF Board member Iris Adler increased this event by 50 new faces this year!

Double Your Donation

Corporate matching gift programs are charitable giving programs setup by corporations in which the company matches donations made by employees to eligible nonprofit organizations. For example, if a donor works for Bank of America and donates $100 to the Hereditary Neuropathy Foundation, Bank of America will double the donation by also writing a check for $100.

Join the conversation

Leave a Comment

3 Comments

  1. Barry Huffman

    I have CMT but not sure what level. I live in the Raleigh, NC area and would be interested in trial at UNC. I have issues with atrophy in my lower legs, hands and vision.

    Reply
  2. Margaret

    I have cmt 1b and live near Chapel Hill. I lead a large group of individuals with cmt. Great news!

    Reply
  3. Leon M Wallace

    I have CMT, but do not know what type. I wear a brace for drop foot on my left leg. My left leg is significantl smaller than my right leg. I also have significant balance issues. I cannot stand on my toes and I walk on the heels of both feet.

    I would like to have my mutation considered. I am 75 year of age and first noticed symptoms about fifteen years ago when I first noticed that I was unable to stand on my toes.

    I would like to participate in the clinical trial if possible.

    Reply

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news